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Abstract
Introduction Immunoglobulin A (IgA) deficiency is the
most common primary immunodeficiency defined as
decreased serum level of IgA in the presence of normal
levels of other immunoglobulin isotypes. Most individuals
with IgA deficiency are asymptomatic and identified
coincidentally. However, some patients may present with
recurrent infections of the respiratory and gastrointestinal
tracts, allergic disorders, and autoimmune manifestations.
IgA and Its Functions Although IgA is the most abundant
antibody isotype produced in the body, its functions are not
clearly understood. Subclass IgA1 in monomeric form is
mainly found in the blood circulation, whereas subclass
IgA2 in dimeric form is the dominant immunoglobulin in
mucosal secretions. Secretory IgA appears to have prime
importance in immune exclusion of pathogenic micro-
organisms and maintenance of intestinal homeostasis.
Despite this critical role, there may be some compensatory
mechanisms that would prevent disease manifestations in
some IgA-deficient individuals.
Pathogenesis In IgA deficiency, a maturation defect in B
cells to produce IgA is commonly observed. Alterations in
transmembrane activator and calcium modulator and cyclo-
philin ligand interactor gene appear to act as disease-
modifying mutations in both IgA deficiency and common
variable immunodeficiency, two diseases which probably
lie in the same spectrum. Certain major histocompatibility
complex haplotypes have been associated with susceptibil-
ity to IgA deficiency.
Conclusion The genetic basis of IgA deficiency remains to
be clarified. Better understanding of the production and
function of IgA is essential in elucidating the disease




Immunoglobulin (Ig) A deficiency (OMIM 137100) is
defined as decreased or absent level of serum IgA in the
presence of normal serum levels of IgG and IgM in a
patient older than 4 years of age, in whom other causes of
hypogammaglobulinemia have been excluded [1, 2]. In
general, serum IgA level of less than 7 mg/dL (0.07 g/L) is
considered as selective IgA deficiency since this concentra-
tion is the lowest detectable limit established by most of the
laboratories. When serum IgA level is higher than 7 mg/dL
but two standard deviations below normal for age, the
condition may be referred to as partial IgA deficiency,
which is quite common. The threshold of 4 years of age is
used to avoid premature diagnosis of IgA deficiency which
may be transient in younger children due to delayed
ontogeny of IgA system after birth.
In here, selective IgA deficiency, with an emphasis on
functions of IgA and disease pathogenesis, along with its
epidemiology, clinical manifestations, disease associations,
treatment approaches, and prognosis will be reviewed.
Immunoglobulin A and Its Functions
First described in serum in 1953, IgA is the most abundant
antibody isotype produced in the body [3–7]. It is the second
dominant isotype in the blood circulation following IgG. It
can be found in both monomeric and polymeric forms.
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DOI 10.1007/s10875-009-9357-xCirculating IgA is in monomeric form, whereas secretory
IgA, in the mucosal secretions of respiratory, intestinal, and
genitourinary systems, is dimeric [4, 6, 7]. The monomeric
structure of serum IgA has two heavy chains, each consisting
of one variable and three constant regions, and two light
chains, each of which is made up of one variable and one
constant region. In humans, there are two subclasses of IgA:
IgA1 and IgA2, constant heavy chains of which are encoded
by two separate α1a n dα2 genes on chromosome 14 [5–7].
The main structural difference between them is that IgA2 has
a shorter hinge region which may render this isotype more
resistant to bacterial proteases in the lumen of gastrointestinal
or respiratory systems [8].
The function of serum IgA in the systemic immune
response has not been clearly understood. Monomeric IgA
in the circulation does not fix the classical pathway of the
complement. However, it may have a role in activation of
phagocytic system by means of the FcRα receptors [5, 7, 9].
It has been proposed that serum IgA binds to FcRα receptor
on the monocytes and granulocytes; thereby, immune
complexes formed by foreign antigens and IgA are cleared
from the circulation by the phagocytic system without
activating the complement system and without causing
inflammation [10, 11]. Serum IgA may also have a role in
controlling the immune system through inhibition of
neutrophil chemotaxis by binding to other inhibitory proteins
such as α-1-antitrypsin and forming complexes [5, 7].
IgA, which is mostly in dimeric form, is the dominant
immunoglobulin in luminal secretions comprising more
thantwothirdsoftotal IgAproductioninthebody[8, 12, 13].
Being more resistant to proteolytic activity of the bacteria,
IgA2 is the main IgA subclass found in secretions, although
both IgA subclasses can form dimers by covalent
interaction with a joining (J) chain attached to the terminal
constant region on the Fc portion. The secretory IgA
dimer contains a secretory component which is actually
the secreted component of the polymeric immunoglobulin
receptor located on the basolateral surface of the mucosal
epithelial cell [13, 14]( F i g .1). More than 95% of secretory
IgA is produced locally. In the gastrointestinal system,
organized Payer’s patches or isolated lymphoid follicles as
well as nonorganized lamina propria can be sites for local IgA
production by Tcell-dependent as well as T cell-independent
mechanisms [15–17]. Intestinal epithelial cells, dendritic
cells, and local stromal cells may be contributing to T cell-
independent production of IgA locally by secreting thymic
stromal lymphopoietin, interleukin (IL)-6, interleukin-10,
tumor necrosis factor-alpha, transforming growth factor beta
(TGF-β1), B-cell activating factor (BAFF), and a
proliferation-inducing ligand (APRIL) [16].
Mucosal membranes in the body cover an approximate
area of 200–400 m
2 harboring an estimate of 15,000–36,000
species and 1,800 genera of microbiota [18–21]. Thus, the
total number of prokaryotic cells exceeds the total number of
eukaryotic cells in the body. Bacteria endogenous to the
intestinal tract, oral cavity, and respiratory and genital tracts
are coated with secretory IgA. As a result, the epithelial
adherence and penetration of bacteria are limited, and the
bacteria are confined to the mucosal surfaces [20]. The IgA
coating of bacteria is traditionally considered to be through
adaptive immunity by Fab-mediated antigen-specific binding.
Recently, it has been proposed that there is a link
between the specific antibody-dependent protection and
the innate glycan-mediated mucosal immunity by means
of N-a n dO-glycans of secretory IgA. It is likely that
glycan-mediated interactions in concert with Fab-mediated
polyreactivity enforce protective functions of secretory
IgA [19, 20, 22, 23]. Despite this critical role of secretory
IgA, surprisingly, some individuals with selective IgA
deficiency are asymptomatic. The diagnosis of IgA
deficiency depends on the measurement of IgA concen-
tration in serum. Secretory IgA level is not determined;
therefore, it is possible that the individuals diagnosed with
selective IgA deficiency may still have some IgA in the
mucosal systems enough to provide some protective
functions. In addition, in most IgA-deficient patients,
seemingly as a compensatory mechanism, production of
secretory IgM is increased [24, 25]. IgA and IgM
have evolutionary, structural, and functional similarities:
homologies between the primary constant chain domains
and the tail pieces, presence of a J chain in both, formation
of polymers, ability to bind the basolateral polymeric Ig
receptor on mucosal epithelial cell, and thereby forming
secretory immunoglobulin molecule that contains the





Fig. 1 Models of a monomeric IgA (left) and a dimeric secretory IgA
(right). The monomer contains IgA1 subclass, whereas the dimer
comprises two IgGA2 subclass monomers. The black circle denotes
the joining (J) chain. The gray chain of five oval links indicates the
secretory piece. Note the shorter hinge region in IgA2 [8]. Modified
from [22]
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there are also some IgA-deficient patients who do not
exhibit compensatory increase in secretory IgM [29].
Most of the commensal bacteria are located in the
gastrointestinal tract [15, 16]. Therefore, maintenance of
intestinal homeostasis is of prime importance. This homeo-
stasis is achieved by means of immune defense mechanisms,
in which secretory IgA has a central role. Growing body of
evidence suggests that protective role of secretory IgA in the
gastrointestinal system is not only through immune exclusion
of bacteria [16–20]. In mice, it has been shown that secretory
IgA is also critical in regulating bacterial communities of the
intestinal lumen. Excessive expansion of anaerobic bacteria
in the entire proximal intestinal system due to lack of
secretory IgA has been reported in activation-induced
cytidine deaminase knockout mice [30]. Similar aberrant
anaerobic expansion is also observed in other mice with IgA
deficiency, e.g., RAG2 −/−,S C I Dm i c e[ 31, 32]. This type of
change in the intestinal microbial ecology may cause
activation of mucosal immune cells including intraepithelial
lymphocytes, cells of the isolated lymphoid follicles, Peyer’s
patches, and mesenteric lymph nodes. In addition, this
activation status may become systemic and involve lympho-
cytes of all germinal centers and lymphoid tissues. Secretory
IgA may also play a role in creating a noninflammatory
host–microbial relationship asa consequence ofits inabilityto
fix the complement and the lack of proinflammatory IgA
receptors on the intestinal macrophages.
Pathogenesis of IgA Deficiency
In IgA-deficient patients, the common finding is a maturation
defectinBcellstoproduceIgA[6, 33]. The defect appears to
involve the stem cells since IgA deficiency can be
transferred by bone marrow transplantation [34]. The
constant α1a n dα2 genes are generally normal except for
rarely described cases of heavy chain gene deletions
involving various segments on chromosome 14 [35]. This
may be the case in sporadic IgA-deficient patients who have
associated IgG2, IgG4, and IgE deficiencies [36–38]. In IgA
deficiency, B cells express IgA; however, they are of
immature phenotype with the coexpression of IgM and
IgD, and they cannot fully develop into IgA-secreting
plasma cells [39, 40]. An intrinsic B cell defect, T helper
cell dysfunction, and suppressor T cells have all been
reported in IgA deficiency. Abnormalities in the cytokine
network such as lack of IL-4, IL-6, IL-7, IL-10, TGF-β,a n d
most recently IL-21 have also been proposed to play a role
in IgA deficiency [6, 41–43]. It is interesting that IL-21
stimulation has been shown to induce class switch recom-
bination to IgG and IgA and differentiation of IgA and IG
secreting plasma cells with restoration of immunoglobulin
production ex vivo in patients with IgA deficiency and
common variable immunodeficiency (CVID) [43].
There is a not well-defined genetic susceptibility in IgA
deficiency. The pedigrees of IgA-deficient individuals show
familial clustering with no distinct Mendelian inheritance
pattern. Autosomal recessive, autosomal dominant, and
sporadic transmission patterns have all been observed [44].
In view of the variation in the inheritance patterns and the
lack of an identified primary genetic defect, it is likely that
IgA deficiency represents a heterogeneous group of genetic
abnormalities such as CVID. Mutations in transmembrane
activator and calcium-modulator and cyclophilin ligand
interactor (TACI, TNFRSF13B) have been found both in a
subset of patients with IgA deficiency or CVID [45]. TACI,
B-cell surface ligand for BAFF and APRIL, has a role in
isotype switching in B cells. The same TACI mutation may
be present in individuals with either IgA deficiency or CVID
in the same family. However, it is controversial whether
TACI mutations have a cause–effect relationship with IgA
deficiency or CVID [46, 47]. Recently, a shared cytotoxic T
lymphocyte-associated protein-4-inducible costimulator
risk locus in IgA deficiency and CVID has been defined
[48]. It is also known that IgA deficiency may progress to
CVID, supporting the notion that IgA deficiency and CVID
lie in the spectrum of the same disease [49, 50].
Associations between IgA deficiency and certain major
histocompatibility complex (MHC) class I, II, and III
haplotypes have been proposed [6, 51–54]. In IgA
deficiency and type 1 diabetes mellitus, HLA-B8 frequency
was found to be increased in earlier studies. HLA-B8
frequency was also higher in IgA deficiency and autoim-
mune disorders. However, these findings may be secondary
to the presence of diabetes mellitus or autoimmune
disorders rather than IgA deficiency itself. In another study
in IgA-deficient individuals, HLA B8 allele was not related
to history of autoimmunity; however, IgA-deficient patients
who had HLA B8 were found to have significantly higher
pneumococcal vaccination responses [55]. A recent study
questioning the frequently implied higher risk for IgA
deficiency with the HLA8 DR3 haplotype has shown that
IgA deficiency is not associated with a distinct haplotype;
rather, the risk is conferred by the common extended MHC
haplotype HLA A1, B8, DR3, and DQ2 (the 8.1 haplotype)
acting in a multiplicative manner [56]. An amino acid
substitution at position 57 of the HLA-DQ beta chain gene
has also been associated with susceptibility to IgA deficiency
[57].
Epidemiology
Selective IgA deficiency is considered as the most common
primary immunodeficiency. The worldwide incidence
12 J Clin Immunol (2010) 30:10–16varies depending on the ethnic background: 1:143 in the
Arabian peninsula [58], 1:163 in Spain [59], 1:252 in
Nigeria [60], 1:875 in England [61], and 1:965 in Brazil
[62]. The incidence is lower among Asian populations, e.g.,
from 1:2,600 to 1:5,300 in China [63] and from 1:14,840 to
1:18,500 in Japan [64]. In general, IgA deficiency is more
common in Caucasians. In the USA, the frequency is
estimated to be from 1:223 to 1:1,000 in community studies
and from 1:333 to 1:3,000 among healthy blood donors [6].
These numbers may in fact be higher because some
individuals with IgA deficiency are asymptomatic, and
there is no established routine screening program for IgA
deficiency. The variation in incidence may also arise from
the fact that the definition of selective IgA deficiency may
differ in each study or registry.
Clinical Manifestations
There is a wide spectrum of clinical findings in IgA
deficiency. Patients with IgA deficiency may be identified
among blood bank donors, without any clinical findings
[6]. In fact, 85–90% of IgA-deficient individuals are
asymptomatic. This high percentage is interesting and still
remains a puzzle to be solved since IgA is such a significant
immunoglobulin in immune defense. Some patients with
IgA deficiency have a tendency to develop recurrent
sinopulmonary infections, gastrointestinal infections and
disorders,allergies, autoimmuneconditions, and malignancies.
Recurrent Sinopulmonary Infections Infections of the
respiratory system are the most common findings in
individuals with IgA deficiency [6, 55, 65]. These
infections are mostly due to bacteria, e.g., Haemophilus
influenzae and Streptococcus pneumoniae. Some patients
may develop end organ damage such as bronchiectasis
secondary to recurring or chronic infections [66]. Patients
with associated antibody deficiency such as IgG2 subclass
deficiency have a higher chance of having more severe
infections and complications.
Gastrointestinal Infections/Disorders IgA-deficient indi-
viduals have a tendency to develop infections and disorders
of the gastrointestinal tract [6, 44, 55]. Giardiasis, malab-
sorption, lactose intolerance, celiac disease, ulcerative colitis,
nodular lymphoid hyperplasia, and malign proliferation are
among the associated diseases. Since the protective barrier of
the gastrointestinal system is impaired in IgA deficiency,
protozoasuchasGiardia lamblia can adhere to the epithelium,
proliferate, and cause infection [67]. Malabsorption may
ensue secondary to structural damage to the intestinal villi.
Even in the absence of infection, some molecules may enter
the subepidermal and submucosal tissue because of the
impaired mucosal clearance of macromolecules and proteins.
This process may facilitate antibody production against
certain antigens and intolerance to certain foods [68]. For
instance, patients with IgA deficiency have a higher chance of
developing celiac disease [69]. Patients with IgA deficiency
are not expected to develop IgA isotype antibodies against
gliadin, tissue transglutaminase, or endomysium; however,
they may have IgG isotype antibodies against those antigens.
Inflammatory bowel diseases, mostly ulcerative colitis, have
also been reported in association with selective IgA deficiency
[6, 55, 70, 71].
Allergic Disorders Allergic disorders appear to be common
in patients with IgA deficiency [6, 55, 65]. The reported
frequency of allergies varies according to the definitions of
both IgA deficiency and allergy and also by the evaluation
methods. In an earlier study, atopy was reported in 58% of
pediatric and adult patients with IgA deficiency [72].
However, in a later study that surveyed 127 IgA-deficient
patients between ages of 2 and 67 years, 13% of patients, a
figure which was probably not higher than in the general
population, was noted to have a history of allergy and
asthma [55]. History of allergy was more common among
younger patients (median age 10.5 years). In 126 Brazilian
children and adolescents with IgA deficiency, 48% had
respiratory allergies and atopic dermatitis [70]. In a recent
prospective Swedish study in children, IgA-deficient patients
were found to have an increased risk of pseudocroup at
year 1 and parentally reported food hypersensitivity at year 4,
both of which were possibly not IgE-mediated, as compared
to children with normal serum levels of IgA [65]. In a more
recent report, in which allergy status was determined more
reliably by clinical presentation and skin prick testing
using 14 common standard allergens, allergic manifesta-
tions including asthma, atopic dermatitis, allergic rhinitis/
conjunctivitis, urticaria, drug allergy, and food allergy
were noted in 84% of patients (age range 4–32 years) with
selective IgA deficiency [71]. In 40.5% of the patients,
allergic manifestations were the presenting symptoms. It is
thought that 25% of patients with IgA deficiency are
identified during evaluation for allergic disorders [6].
Autoimmunity Autoimmune diseases are among the most
important clinical manifestations in IgA deficiency [6, 55,
70]. Autoantibodies, such as antibodies against sulfatide,
Jo-1, cardiolipin, phosphatidylserine, and collagen can be
detected in IgA-deficient patients even if overt clinical
disease is not the case [73]. It has been long known that
several autoimmune disorders may occur in association
with IgA deficiency. In a 2004 study, the second most
common association with IgA deficiency after recurrent
infections was autoimmunity (28%) [55]. Autoimmunity
was more prevalent in adults (median age 29 years) and in
J Clin Immunol (2010) 30:10–16 13females (24 autoimmune conditions in females versus 14 in
males in a total of 34 subjects). The most common
autoimmune condition was idiopathic thrombocytopenic
purpura followed by hemolytic anemia, juvenile rheumatoid
arthritis, thyroiditis, systemic lupus erythematosus, and
presence of various autoantibodies. In a younger population,
autoimmune disorders, i.e., thyroid disease, arthropathy,
celiac disease, anemia, and systemic lupus erythematosus,
were detected in19% of patients. This figurevariesfrom20%
to30%basedontheagerangeofstudiedpopulations[71, 74].
In addition, autoimmune conditions were found to be higher
among relatives of IgA-deficient patients. Of the first-degree
relatives of IgA-deficient patients, 10% had autoimmunity
compared to an estimate of 5% in the general population.
IgA-deficient patients may develop anti-IgA antibodies
which have a potential to cause anaphylactic reactions upon
transfusion of any blood product, such as red blood cells or
platelets, which contains trace amounts of IgA [75, 76]. The
anti-IgA antibody capable of causing a type I hypersensitivity
reaction would be of IgE isotype. Therefore, testing for the
IgE isotype antibodies against IgA would be meaningful
in determining the possibility of a blood transfusion
reaction in an IgA-deficient patient. However, this testing
is not readily available in most of the laboratories.
Instead, IgG anti-IgA antibodies may be measured as a
screening tool.
Malignancy The association of IgA deficiency and malig-
nancies have been reported in sporadic cases, particularly at
older ages.Those are usually oflymphoidand gastrointestinal
origins [55, 77].
Laboratory Evaluation
IgA deficiency should be a consideration in a patient with
recurrent respiratory and gastrointestinal infections, aller-
gies, and autoimmune disorders [1, 2]. Immunologic
evaluation for IgA deficiency is also warranted in case of
anaphylaxis secondary to a blood product transfusion,
celiac disease, and a family history of IgA deficiency and/
or CVID. It would be prudent to take into account the
medications that may cause decreased serum levels of IgA
in the patient. Evaluation of a suspected IgA deficiency
would generally include a complete blood count with
differential, quantitative serum immunoglobulin levels,
serum IgG subclasses, specific antibody response to protein
and polysaccharide antigens, and lymphocyte subsets. In
addition, pertinent laboratory testing for the associated
conditions, e.g., recurrent infections, allergies, or celiac
disease, should be performed. Celiac disease screening
should include IgG isotype antibodies against gliadin and
tissue transglutaminase since IgA isotype antibodies may
not be detected because of the IgA deficiency.
Management
IgA-deficient patients who are diagnosed coincidentally and/
or who do not have any symptoms do not need any treatment.
However, awareness and education are of prime importance,
particularly to prevent a potential anaphylactic reaction
secondary to blood transfusion. In this regard, patients with
selective IgA deficiency should be recommended to wear a
medical alert bracelet. In case of a blood transfusion
requirement, the patient, ideally, should be screened for
anti-IgA antibodies. The blood product should be prepared
from an IgA-deficient individual, or saline-washed red blood
cells shouldbe the choice. All blood productsshouldbe given
with caution, and the staff should be prepared to treat a
potential anaphylactic reaction.
In IgA deficiency, the mainstay of treatment is the
treatment of associated diseases. If the patient experiences
recurrent infections, daily prophylactic antibiotics on a
continuous or seasonal intermittent basis may be beneficial.
In case of associated IgG subclass deficiency and/or
specific antibody deficiency, immunoglobulin treatment
via venous or subcutaneous route with a product that
contains minimal IgA may be given. Standard treatment
approach is entertained in case of an associated allergic
disorder or autoimmune condition.
Prognosis
The prognosis is good in patients with IgA deficiency if it
is not associated with a significant disease. IgA deficiency
in children may resolve over time. However, it is also
known that IgA deficiency may progress into CVID, which
has a less favorable outcome. Therefore, a patient with IgA
deficiency,once identified,would deserve a regular follow-up
of clinical and immunological findings.
In summary, although IgA deficiency is the most
common primary immunodeficiency recognized for al-
most a half century, its genetic basis remains to be
defined, and the cellular and molecular mechanisms
involved in IgA physiology and functions as well as in
disease pathogenesis need to be further elucidated.
Molecular mechanisms of physiological and pathological
actions are discussed in the accompanying review by Dr.
Renato Monteiro.
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